Advertisement

Osteoporosis International

, Volume 25, Issue 1, pp 205–210 | Cite as

Comparison of hip fracture and osteoporosis medication prescription rates across Canadian provinces

  • R. G. Crilly
  • M. Kloseck
  • B. Chesworth
  • S. Mequanint
  • E. Sadowski
  • J. Gilliland
Original Article

Abstract

Summary

The study explores osteoporosis medication prescribing across Canadian provinces and any impact on hip fracture rates. Despite a marked variation in the prescribing of such medication, there is no effect on the hip fracture rate in either gender or any age group, suggesting either poor targeting or lack of efficacy.

Introduction

Hip fractures are the most disabling and costly of osteoporotic fractures, and a reduction in the risk of hip fracture is an expectation of osteoporosis medications. In this study, we have compared the use of osteoporosis medication across Canadian provinces with the rate of hip fractures in the same regions.

Methods

Three years of hip fracture data (2007–2009 inclusive) were obtained from the Canadian Institute for Health Information for all Canadian provinces excluding Quebec. Population information was obtained from Statistics Canada and medication information from the Brogan Inc. database. Because osteoporosis medication is available daily, weekly, monthly, and yearly, medication prescriptions were converted to “units” of prescribing, so that a once a year infusion represented 365 units, a monthly prescription 30 units, and so forth.

Results

There is a fourfold difference in prescribing across provinces but no corresponding variation in hip fracture rate. No significant correlation exists between prescribing load and hip fracture rate. This was true for all age groups, both genders, and for both intertrochanteric and subcapital hip fracture.

Conclusions

We find no association between osteoporosis medication prescribing and hip fracture rate. Possible explanations include insufficient numbers of at-risk patients on treatment, inappropriate targeting, and either lack of efficacy or efficacy limited to only certain subgroups of patients such as those with demonstrable trabecular osteoporosis.

Keywords

Hip fracture Medication Osteoporosis Prescription rates 

Notes

Acknowledgments

Our thanks are due to Warner Chilcott Pharmaceuticals for financial support for the study and for facilitating access to the medication data and to Brogan Inc. for the provision of the medication data.

Conflicts of interest

None.

References

  1. 1.
    Seeman E (2012) Nonvertebral fractures: as good as it gets? International Osteoporosis Foundation overview 12(2). www.iofbonehealth.org/volume-12-issue-2. Accessed 30 January 2013
  2. 2.
    McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier J, Reginster JY (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 334(5):333–340CrossRefGoogle Scholar
  3. 3.
    Lyles K, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357(18):1799–1809PubMedCrossRefGoogle Scholar
  4. 4.
    Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 280(24):2077–2082PubMedCrossRefGoogle Scholar
  5. 5.
    Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J, Vogt TM (1993) Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 342(8837):72–75CrossRefGoogle Scholar
  6. 6.
    Cummings SR (1985) Are patients with hip fractures more osteoporotic? Review of the evidence. Am J Med 78(3):487–494PubMedCrossRefGoogle Scholar
  7. 7.
    Crilly RG, Cox L (2013) A comparison of bone density and bone morphology in those presenting with hip fractures, spinal fractures or a combination of the two. BMC Musculoskelet Disord 14:68. doi: 10.1186/1471-2474-14-68 PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Stone KL, Seeley DG, Lui LY, Cauley JA, Ensrud K, Browner WS, Nevitt MC, Cummings SR (2003) BMC at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res 18(11):1947–1954PubMedCrossRefGoogle Scholar
  9. 9.
    Siris ES, Chen Y-T, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, Berger ML (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164(1):1108–1112PubMedCrossRefGoogle Scholar
  10. 10.
    Leslie WD, O’Donnell S, Jean S, Legacé C, Walsh P, Bancej C, Morin S, Hanley DA, Papaioannou A (2009) Trends in hip fracture rates in Canada. JAMA 302(8):883–889PubMedCrossRefGoogle Scholar
  11. 11.
    Hartholt KA, Oudshoorn C, Zielinski SM, Burgers PT, Panneman MJ, van Beeck EF, Patka P (2011) The epidemic of hip fractures: are we on the right track? PLoS One 6(7):e22227. doi: 10.1371/journal.pone.0022227 PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Guerra-García MM, Rodríguez-Fernández JB, Puga-Sarmiento E, Charle-Crespo MÁ, Gomes-Carvalho CS, Prejigueiro-Santás A (2011) Incidence of hip fractures due to osteoporosis in relation to the prescription of drugs for their prevention and treatment in Galicia, Spain. Aten Primaria 43(2):82–88. doi: 10.1016/j.aprim.2010.04.010, Epub 2010 Jun 15. SpanishPubMedCrossRefGoogle Scholar
  13. 13.
    Nakamura N, Kyou T, Takaoka K, Ohzono K, Ono K (1992) Bone mineral density in the proximal femur and hip fracture type in the elderly. J Bone Miner Res 7(7):755–759PubMedCrossRefGoogle Scholar
  14. 14.
    Osteoporosis Canada (2012) www.osteoporosis.ca/index.php/ci_id/5521/la_id/1.htm. Accessed 12 February 2013
  15. 15.
    Jones TM, Petrella RJ, Crilly R (2008) Determinants of persistence with weekly bisphosphonates in patients with osteoporosis. J Rheumatol 35(9):1865–1873PubMedGoogle Scholar
  16. 16.
    Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, Hanley DA, Hodsman A, Jamal SA, Kaiser SM, Kvern B, Siminoski K, Leslie WD (2010) clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ. doi: 10.1503/cmaj.100771 PubMedCentralPubMedGoogle Scholar
  17. 17.
    Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA (2012) Does osteoporosis therapy invalidate FRAX® for fracture prediction? J Bone Miner Res 27:1243–1251PubMedCrossRefGoogle Scholar
  18. 18.
    FRAX WHO Fracture Risk Assessment Tool http://www.shef.ac.uk/FRAX/tool.j Accessed 12 February 2013
  19. 19.
    Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee RY, Wong JB (2004) Effect of vitamin D on falls. A meta-analysis. JAMA 291:1999–2006PubMedCrossRefGoogle Scholar
  20. 20.
    O’Loughlin JL, Robitaille Y, Boivin JF, Suissa S (1993) Incidence of and risk factors for falls and injurious falls among the community-dwelling elderly. Am J Epidemiol 137:342–352PubMedGoogle Scholar
  21. 21.
    Cummings SR, San Martin J, McClung MR, Siris E et al (2009) Denosumab for prevention of fractures in Postmenopausal women with osteoporosis. N Engl J Med 361:756–765PubMedCrossRefGoogle Scholar
  22. 22.
    Rabenda V, Vanoverloop J, Fabri V, Mertens R, Sumkay F, Vannecke C, Deswaef A, Verpooten GA, Reginster JY (2008) Low incidence of anti-osteoporosis treatment after hip fracture. Bone Joint Surg Am 90(10):2142–2148CrossRefGoogle Scholar
  23. 23.
    Jennings LA, Auerbach AD, Maselli J, Pekow PS, Lindenauer PK, Lee SJ (2010) Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture. J Am Geriatr Soc 58:650–657PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2013

Authors and Affiliations

  • R. G. Crilly
    • 1
    • 5
  • M. Kloseck
    • 2
  • B. Chesworth
    • 2
  • S. Mequanint
    • 3
  • E. Sadowski
    • 2
  • J. Gilliland
    • 4
  1. 1.Division of Geriatric Medicine, Faculty of MedicineThe University of Western OntarioLondonCanada
  2. 2.Faculty of Health SciencesThe University of Western OntarioLondonCanada
  3. 3.Schulich School of Medicine & DentistryThe University of Western OntarioLondonCanada
  4. 4.Department of GeographyThe University of Western OntarioLondonCanada
  5. 5.Division of Geriatric MedicineParkwood HospitalLondonCanada

Personalised recommendations